Table 2.
Clinical trials of targeted tumor glycosylation drugs in phase 2 and subsequent research stages.
| Drug Candidate | Target | Drug Type | Conditions | Phase | ClinicalTrials.gov ID | Study Start | Study Status | |
|---|---|---|---|---|---|---|---|---|
| 1 | Moxetumomab pasudotox | CD22 | ADC | Hairy cell leukemia | 2 | NCT00923013 | 2008.10 | Active, not recruiting |
| Non-Hodgkin lymphomaChronic lymphocytic leukemia | 2 | NCT01030536 | 2010.02 | Completed | ||||
| Hairy cell leukemia | 3 | NCT01829711 | 2013.04 | Completed | ||||
| 2 | Inotuzumab ozogamicin | CD22 | ADC | B-cell lymphoma | 1/2 | NCT00299494 | 2006.05 | Completed |
| B-cell lymphoma | 2 | NCT00867087 | 2009.06 | Completed | ||||
| Lymphoma | 2 | NCT00868608 | 2009.07 | Completed | ||||
| Acute lymphoblastic leukemia | 2 | NCT01134575 | 2010.06 | Completed | ||||
| B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1;B acute lymphoblastic leukemia, Philadelphia chromosome negativeBurkitt-like lymphoma with 11q aberrationHigh grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangementsHigh grade B-cell lymphoma, not otherwise specifiedRecurrent B acute lymphoblastic leukemiaRecurrent Burkitt lymphomaRefractory B acute lymphoblastic leukemiaRefractory Burkitt lymphoma | 1/2 | NCT01371630 | 2011.08 | Recruiting | ||||
| Acute lymphocytic leukemia | 2 | NCT01363297 | 2011.08 | Completed | ||||
| Acute lymphoblastic leukemia | 3 | NCT01564784 | 2012.08 | Completed | ||||
| Hematopoietic and lymphoid cell neoplasm | 1/2 | NCT01664910 | 2012.10 | Completed | ||||
| Diffuse large B-cell lymphoma | 1/2 | NCT01562990 | 2012.12 | Completed | ||||
| Diffuse large B-cell lymphoma | 2 | NCT01679119 | 2013.10 | Completed | ||||
| B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1Blast phase chronic myelogenous leukemia, BCR-ABL1 PositiveBlasts more than 5 percent of bone marrow nucleated cellsPhiladelphia chromosome-positive, BCR-ABL1-positive chronic myelogenous leukemiaRecurrent chronic myelogenous leukemia, BCR-ABL1 positiveRefractory chronic myelogenous leukemia, BCR-ABL1 positive | 1/2 | NCT02311998 | 2015.04 | Completed | ||||
| B acute lymphoblastic leukemiaB lymphoblastic leukemia | 2 | NCT02877303 | 2016.11 | Recruiting | ||||
| Recurrent B acute lymphoblastic leukemia Recurrent B lymphoblastic leukemiaRefractory B acute lymphoblastic leukemiaRefractory B lymphoblastic lymphoma |
2 | NCT02981628 | 2017.06 | Active, not recruiting | ||||
| Acute lymphocytic leukemia | 1/2 | NCT03104491 | 2017.07 | Recruiting | ||||
| Acute lymphoblastic leukemia-Ph-negative CD22+ B-cell precursor | 2 | NCT03249870 | 2017.12 | Active, not recruiting | ||||
| Acute lymphoblastic leukemiaB acute lymphoblastic leukemiaRecurrent B acute lymphoblastic leukemia | 2 | NCT03441061 | 2018.02 | Recruiting | ||||
| Precursor cell lymphoblastic leukemia | 2 | NCT03460522 | 2018.05 | Recruiting | ||||
| Acute lymphoblastic leukemia Hyperbilirubinemia |
2 | NCT03564678 | 2018.05 | Recruiting | ||||
| Acute lymphoblastic leukemia | 2 | NCT03913559 | 2019.05 | Recruiting | ||||
| B acute lymphoblastic leukemia, Philadelphia chromosome negativeRecurrent B acute lymphoblastic leukemiaRefractory B acute lymphoblastic leukemia | 2 | NCT03739814 | 2019.05 | Recruiting | ||||
| Leukemia, precursor B-cell lymphoblasticLeukemia-lymphoma;Acute lymphoblastic leukemia | 4 | NCT03677596 | 2019.07 | Completed | ||||
| Acute lymphoblastic leukemiaB acute lymphoblastic leukemiaLymphocytic neoplasmLymphoma | 2 | NCT03856216 | 2019.10 | Recruiting | ||||
| B acute lymphoblastic leukemiaB lymphoblastic leukemiaCentral nervous system leukemiaMixed phenotype acute leukemiaTesticular leukemia | 3 | NCT03959085 | 2019.10 | Recruiting | ||||
| Leukemia, acute lymphoblastic | 3 | NCT04307576 | 2020.07 | Recruiting | ||||
| B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 3 | NCT04530565 | 2021.01 | Recruiting | ||||
| Lymphoblastic leukemiaAcute lymphoblastic leukemiaPh+ acute lymphoblastic leukemia | 2 | NCT04747912 | 2021.03 | Recruiting | ||||
| Acute lymphocytic leukemia | 2 | NCT05456698 | 2022.08 | Not yet recruiting | ||||
| ALLMRD-positive | 2 | NCT05940961 | 2022.08 | Recruiting | ||||
| Acute lymphoblastic leukemia | 4 | NCT05687032 | 2023.02 | Not yet recruiting | ||||
| B acute lymphoblastic leukemia B lymphoblastic lymphoma |
2 | NCT05303792 | 2023.02 | Recruiting | ||||
| Acute lymphoblastic leukemia | 2 | NCT05748171 | 2023.05 | Recruiting | ||||
| Leukemia | 2 | NCT05645718 | 2023.07 | Recruiting | ||||
| Acute lymphoblastic leukemia | 1/2 | NCT06087419 | 2023.10 | Not yet recruiting | ||||
| Relapsed/refractory B-cell acute lymphocytic leukemia | 1/2 | NCT06287229 | 2024.08 | Not yet recruiting | ||||
| 3 | Epratuzumab | CD22 | ADC | LeukemiaLymphoma | 1/2 | NCT00004107 | 1998.02 | Completed |
| LeukemiaLymphoma | 1/2 | NCT00004084 | 1998.04 | Completed | ||||
| Non-Hodgkin's lymphomaLymphoma, B-Cell | 1/2 | NCT00061425 | 2000.08 | Completed | ||||
| NHLB-cell NHLNon-Hodgkin's Lymphoma | 1/2 | NCT00421395 | 2002.08 | Completed | ||||
| Recurrent childhood acute lymphoblastic leukemia | 2 | NCT00098839 | 2005.02 | Completed | ||||
| Lymphoma | 2 | NCT00301821 | 2006.01 | Completed | ||||
| Non-Hodgkin's lymphoma | 2 | NCT00044902 | 2007.12 | Completed | ||||
| Lymphoma | 2 | NCT00553501 | 2008.03 | Completed | ||||
| Leukemia | 2 | NCT00945815 | 2010.09 | Completed | ||||
| B ALL;CD22+ expressionRefractory B-ALL | 2 | NCT01219816 | 2010.11 | Completed | ||||
| Acute lymphoblastic leukemia (ALL) | 3 | NCT01802814 | 2014.05 | Completed | ||||
| Blasts 5 percent or more of bone marrow nucleated cellsCD22 positivePhiladelphia chromosome positiveRecurrent B acute lymphoblastic leukemiaRefractory B acute lymphoblastic leukemia | 1/2 | NCT03698552 | 2018.08 | Recruiting | ||||
| 4 | Gemtuzumab ozogamycin | CD33 | ADC | Leukemia, myelocytic, acute | 3 | NCT00962767 | 2002.05 | Completed |
| Leukemia, myelocytic, acute | 3 | NCT00136084 | 2002.08 | Completed | ||||
| Leukemia | 3 | NCT00052299 | 2002.09 | Completed | ||||
| Leukemia | 3 | NCT00049517 | 2002.12 | Completed | ||||
| Acute myeloid leukemia | 3 | NCT00476541 | 2004.01 | Completed | ||||
| Leukemia | 3 | NCT00085709 | 2004.07 | Completed | ||||
| Leukemia;Myelodysplastic syndromes | 3 | NCT00121303 | 2005.01 | Completed | ||||
| Leukemia | 3 | NCT00372593 | 2006.08 | Completed | ||||
| Leukemia; myelodysplastic syndromes | 2/3 | NCT00454480 | 2006.08 | Completed | ||||
| Leukemia | 3 | NCT00492856 | 2007.06 | Completed | ||||
| Acute myeloid leukemia | 3 | NCT00860639 | 2007.10 | Completed | ||||
| Acute myeloid leukemia | 3 | NCT00927498 | 2007.12 | Completed | ||||
| Acute myeloid leukemia | 2/3 | NCT00909168 | 2008.03 | Completed | ||||
| Acute myeloid leukemia | 3 | NCT00893399 | 2010.05 | Completed | ||||
| Acute myeloid leukemia | 2/3 | NCT02473146 | 2015.11 | Completed | ||||
| 5 | Lintuzumab | CD33 | ADC | Leukemia | 2 | NCT00002609 | 1994.08 | Completed |
| LeukemiaMyelodysplastic syndromesNeutropenia | 2 | NCT00002800 | 1996.07 | Completed | ||||
| Leukemia | 2 | NCT00016159 | 2000.01 | Completed | ||||
| Acute myeloid leukemia | 2 | NCT00528333 | 2007.09 | Completed | ||||
| 6 | Abagovomab | MUC1 | mAbs | Ovarian cancerFallopian tube neoplasmsPeritoneal neoplasms | 1/2 | NCT00103545 | 2003.07 | Completed |
| 7 | BM7PE | MUC1 | ADC | Colorectal cancer metastatic | 1/2 | NCT04550897 | 2020.08 | Recruiting |
| 8 | Oregovomab | MUC16 | mAbs | Ovarian neoplasms | 2 | NCT01616303 | 2012.06 | Completed |
| Pancreatic adenocarcinomaResectable pancreatic carcinomaStage I-III pancreatic cancer | 2 | NCT01959672 | 2013.09 | Completed | ||||
| Carcinoma, ovarian epithelialOvarian neoplasmsOvarian cancerOvarian serous adenocarcinomaFallopian tube neoplasmsFallopian tube adenocarcinomaFallopian tube serous adenocarcinomaPeritoneal cancerPeritoneal carcinomaPeritoneal neoplasms | 3 | NCT04498117 | 2020.08 | Active, not recruiting | ||||
| 9 | REGN-4018 | MUC16/CD3 | BiTE | Recurrent ovarian cancerRecurrent fallopian tube cancerRecurrent primary peritoneal cancerRecurrent endometrial cancer | 1/2 | NCT03564340 | 2018.05 | Recruiting |
| Ovarian cancerFallopian tube cancerPrimary peritoneal cancer | 1/2 | NCT04590326 | 2020.12 | Recruiting | ||||
| 10 | REGN-5668 | MUC16/CD28 | BiTE | Ovarian cancerFallopian tube cancerPrimary peritoneal cancer | 1/2 | NCT04590326 | 2020.12 | Recruiting |
| 11 | Dinutuximab | GD2 | mAbs | High-risk neuroblastoma | 3 | NCT01041638 | 2009.12 | Completed |
| Neuroblastoma, recurrent | 2 | NCT02258815 | 2010.08 | Completed | ||||
| Neuroblastoma | 1/2 | NCT01592045 | 2012.08 | Completed | ||||
| GanglioneuroblastomaRecurrent neuroblastoma | 2 | NCT01767194 | 2013.02 | Completed | ||||
| Metastatic malignant neoplasm in the lungMetastatic osteosarcomaRecurrent osteosarcoma | 2 | NCT02484443 | 2016.02 | Completed | ||||
| 12 | Naxitamab | GD2 | mAbs | Recurrent osteosarcoma | 2 | NCT02502786 | 2015.07 | Recruiting |
| Neuroblastoma | 2 | NCT03363373 | 2018.04 | Recruiting | ||||
| Neuroblastoma recurrent | 2 | NCT05754684 | 2022.01 | Recruiting | ||||
| High-risk neuroblastoma | 2 | NCT05489887 | 2022.09 | Recruiting | ||||
| Neuroblastoma | 4 | NCT05421897 | 2022.10 | Recruiting | ||||
| Neuroblastoma | 2 | NCT06013618 | 2023.06 | Recruiting | ||||
| Ewing sarcoma | 2 | NCT05968768 | 2023.10 | Recruiting | ||||
| Neuroblastoma | 4 | NCT06047535 | 2023.10 | Active, not recruiting | ||||
| Anatomic stage IV breast cancer AJCC v8HER2-negative breast carcinoma | 1/2 | NCT06026657 | 2024.03 | Recruiting | ||||
| 13 | Ecromeximab | GD3 | mAbs | Metastatic melanomaCutaneous melanoma | 2 | NCT00679289 | 2008.03 | Completed |
| 14 | BMS-986012 | FucGM1 | mAbs | Small cell lung cancer | 1/2 | NCT02247349 | 2014.11 | Completed |
| Extensive-stage small cell lung cancer | 2 | NCT04702880 | 2021.03 | Recruiting | ||||
| 15 | PankoMab-GEX™ | Tn | mAbs | Ovarian epithelial cancer recurrentFallopian tube cancerPrimary peritoneal cancer | 2 | NCT01899599 | 2013.09 | Completed |
Note: 1. Data source: https://www.clinicaltrials.gov/;2. Clinical trials whose statuses were shown to be terminated and unknown were not included;3. The clinical trials of gemtuzumab ozogamycin are numerous, with only phase 3 and subsequent clinical trials listed in the table.